

Catalog# BP-50210

Farletuzumab ecteribulin

Description:

Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FR α) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a Drug-to-antibody ratio (DAR) of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity. This product is for research use only.

Product Details	
CAS No.	2407465-18-1
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Farletuzumab (anti-FR α)
Target	Human folate receptor alpha (FR α)
ADC cytotoxin (drug)	MMAE
Purity	99%
DAR	4.0
Molecular Weight	149kDa
Formulation	1xPBS
Purification	Size exclusive column
Storage conditions	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.